摘要
背景与目的:目前的流行病学研究报告了他汀类药物或二甲双胍对胰腺癌整体生存率的影响。本文通过文献综述和Meta分析,总结了有关胰腺癌患者使用他汀类药物或二甲双胍与患者整体生存率之间的关系的研究成果。方法:在计算机数据库(PubMed、ISI Web of Science、MEDLINE、Cochrane、Scopus、Google学者)中,系统地研究了他汀类和二甲双胍类药物与胰腺癌整体生存率的关系。采用随机效应模型,基于危险比(HRs)和95%置信区间(CIS)进行元分析。采用I2统计量检验研究之间的异质性,并进行敏感性分析,以评估研究结果的稳健性。结果:在所鉴定的116篇与他汀类相关的文章中,有6篇涉及12,057例患者的回顾性队列研究。研究之间存在显著的异质性。胰腺癌患者应用他汀类药物可提高生存率(Meta-HR=0.75;95%CI:0.59,0.90;P<0.001)。在311篇与二甲双胍有关的文章中,8项回顾性队列研究和2项随机临床试验,代表3,042名患者。二甲双胍的使用与胰腺癌患者的总生存期有关(Meta-HR=0.79;95%CI:0.70,0.92,P<0.001)。结论:胰腺癌患者生存时间的改善与他汀类药物或二甲双胍的使用有关。由于原始研究的多个来源的异质性,这些发现应慎重考虑,并与更大的前瞻性个人水平的研究证实。
关键词: 他汀类,二甲双胍,胰腺癌,总生存率,Meta分析,癌症药物。
Current Medicinal Chemistry
Title:Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis
Volume: 25 Issue: 22
关键词: 他汀类,二甲双胍,胰腺癌,总生存率,Meta分析,癌症药物。
摘要: Background and Objective: Current epidemiological studies report conflicting results for the effect of statin or metformin on pancreatic cancer overall survival. This literature review and meta-analysis summarize the studies reporting an association between statin or metformin use and overall survival of pancreatic cancer patients.
Methods: We systematically searched for studies about the association between statin or metformin use and pancreatic cancer overall survival in electronic databases (PubMed, ISI Web of Science, MEDLINE, Cochrane, Scopus, Google Scholar). A meta-analysis based on hazard ratios (HRs) and 95% confidence intervals (CIs) was performed using random effect models. Heterogeneity between the studies was examined using I2 statistics, and sensitivity analyses were conducted to assess the robustness of the findings.
Results: Of 116 statin-related articles identified, 6 retrospective cohort studies representing 12,057 patients were included. There was significant heterogeneity between studies. Statin use was associated with improved survival among pancreatic cancer patients (meta-HR = 0.75; 95% CI: 0.59, 0.90; P < 0.001). Of 311 metformin-related articles, 8 retrospective cohort studies and 2 randomized clinical trials, representing 3,042 patients were identified. Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0.79; 95% CI: 0.70, 0.92, P < 0.001), and significant heterogeneity was observed between studies.
Conclusion: Our findings suggest that the improved survival time of pancreatic cancer patients are associated with statin or metformin use. Due to the multiple sources of heterogeneity of the original studies, these findings should be considered cautiously, and confirmed with larger prospective individual-level studies.
Export Options
About this article
Cite this article as:
Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis, Current Medicinal Chemistry 2018; 25 (22) . https://dx.doi.org/10.2174/0929867324666170412145232
DOI https://dx.doi.org/10.2174/0929867324666170412145232 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin
Mini-Reviews in Medicinal Chemistry Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Aqueous Extract of Argania spinosa L. Fruits Ameliorates Diabetes in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Induction of Autophagic Cell Death in Apoptosis-resistant Pancreatic Cancer Cells using Benzo[α]phenoxazines Derivatives, 10-methyl-benzo[α]phenoxazine-5-one and benzo[α]phenoxazine-5-one
Anti-Cancer Agents in Medicinal Chemistry Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
Current Molecular Medicine The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives
Current Pharmaceutical Design